New Protein Biomarkers and Technology for Improving Diagnosis and Outcome Prediction in Mild TBI

Madrid Health Service

Status

Enrolling

Conditions

Mild Traumatic Brain Injury

Treatments

Other: Serum and saliva biomarkers

Study type

Observational

Funder types

Other

Identifiers

NCT06327776

21/709

Details and patient eligibility

About

Mild traumatic brain injury(mTBI) is a common cause of consultation to the emergency rooms worldwide and is the most common form of traumatic brain injury. Though classified as mild, as many as 40% of patients suffering mTBI do not make complete recoveries or present persistent symptoms. The present study is intended to determine long term outcome of patients suffering mTBI and to establish new prognostic models with the use of serum and saliva based biomarkers. For this purpose this study will not exclude patients regarding their comorbidities.

Enrollment

1,000 estimated patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mild TBI (GCS 13-15 on admission)
Blood sample obtained ≤24h after injury

Exclusion criteria

GCS 3-12 on admission
Time of injury unknown
Time to injury exceeding 24 hours
Primary admission for non-traumatic neurological disorder (e.g., stroke, spontaneous, intracranial hematoma)
Penetrating head trauma
Patient with mechanical ventilation from the trauma scene or prehospital management.
Venipuncture not feasible
Subject under judiciary control